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Osteoarthritis (OA) treatment is a major orthopedic challenge given that there is no
ideal drug capable to reverse or stop the progression of the OA. In that regard,
bisphosphonates have been proposed as potential disease-modifying drugs due to their
possible chondroprotective effect related to obtaining a greater subchondral bone quality.
However, their effectiveness in OA is still controversial and additionally, there is little
evidence focused on their long-term effect in preclinical studies. The aim of this study was
to evaluate the risedronate quantitative effect on articular and subchondral periarticular
bone by histomorphometry, in an experimental rabbit model in an advanced stage of
OA. Twenty-four adult New Zealand rabbits were included in the study. OA was surgically
induced in one randomly chosen knee, using the contralateral as healthy control. Animals
were divided into three groups (n = 8): placebo control group, sham surgery group
and risedronate-treated group. After 24 weeks of treatment, cartilage and subchondral
femorotibial pathology was evaluated by micro-computed tomography (micro-CT) and
undecalcified histology. The research results demonstrated that the experimental animal
model induced osteoarthritic changes in the operated joints, showing an increased
cartilage thickness and fibrillation associated with underlying subchondral bone thinning
and decreased trabecular bone quality. These changes were especially highlighted in the
medial tibial compartments as a possible response to surgical instability. Regarding the
trabecular analysis, significant correlations were found between 2D histomorphometry
and 3D imaging micro-CT for the trabecular bone volume, trabecular separation, and the
trabecular number. However, these associations were not strongly correlated, obtaining
more precise measurements in the micro-CT analysis. Concerning the long-term
risedronate treatment, it did not seem to have the capacity to reduce the osteoarthritic
hypertrophic cartilage response and failed to diminish the superficial cartilage damage
or prevent the trabecular bone loss. This study provides novel information about the
quantitative effect of long-term risedronate use on synovial joint tissues.
Keywords: cartilage, histomorphometry, long-term therapy, osteoarthritis, rabbit model, risedronate, subchondral
bone
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INTRODUCTION
Osteoarthritis (OA) is a multifactorial and progressive disease
of the synovial joints associated with dysfunction and pain.
Morphologically, it is characterized by gradual articular cartilage
deterioration, subchondral bone sclerosis, synovial inflammation
and osteophyte formation (1). Although OA involves all the
synovial joint tissues, both the articular cartilage layer and the
subchondral periarticular bone seem to show the most severe
impact of the disease (2). However, the exact relationship between
their roles in the onset of OA still remain controversial (3,
4). Nevertheless, recent research has shown that the cartilage
degeneration was strongly related and occurred in parallel to
subchondral bone changes (5).
It is well-known that during the OA process, the subchondral
bone compartment undergoes structural changes including,
among others, a thickened subchondral plate and an increased
bone turnover, which could affect the overlying hyaline
cartilage in response to altered biochemical properties (6).
Bisphosphonates (BPs) have therefore been proposed as
potential disease-modifying drugs due to their modulator
function of inhibiting the bone-resorption activity (3, 7).
Experimental studies with animal models have shown positive
chondroprotective effects of various BPs associated with
obtaining a greater subchondral bone quality. Specifically,
beneficial effects on both cartilage and bone compartment have
been demonstrated, among others, with alendronate (8–12),
zoledronic acid (13, 14), pamidronate (15), and risedronate
(11, 16, 17). By contrast, other preclinical studies have shown no
disease-modifying effect, failing to prevent the cartilage erosion
(18–21) and the osteophyte formation (19, 21–23).
Animal models have been widely used in OA research and
have a critical role in studying the articular structural changes
and evaluating the therapy efficacy of several drugs. However, one
should take into account that OA is a complex and heterogeneous
disease and consequently, no single animal model is capable
to represent all aspects of the pathology process (7, 24). Thus,
numerous surgical models have been outlined in different animal
species, mainly focusing on the synovial joint of the knee (25, 26).
They are based on a combination of joint instability, altered
load bearing and inflammation to induce the osteoarthritic
changes (7, 27). Small animal models are thoroughly used in
OA research due to their easy handling, housing availability, and
low costs (25). Specifically, rabbits are one of the most used OA
models in preclinical studies. The induced methods described in
these studies included the anterior cruciate ligament transection
(ACLT) with or without total or partial meniscectomy andmedial
and collateral ligament section, among others (28, 29). The ACLT
surgical instability technique in skeletally mature rabbits has
been demonstrated as a reproducible and efficacious model and
is capable to reproduce the cartilage, synovial and subchondral
bone changes associated with OA, similarly to those observed
in human disease (29). Although some anatomical similarities
with the human knee have been described, there are notable
differences in cartilage composition and joint mechanics when
comparing rabbits and humans (30). Rabbit cartilage is∼10 times
thinner than human cartilage and shows higher chondrocyte
density (31). Additionally, one should know the load-bearing
pattern of the animal model used, because there are remarkable
differences depending on the species of the selected animal.
Concerning rabbits, they appear to show a marked load-bearing
in lateral compartments, unlike other species such as rodents,
guinea pigs, or humans. It has therefore been observed that
surgical medial meniscectomy in rabbits results in slower and less
severe degenerative joint changes compared with lateral surgical
procedures, which probably make the medial interventions more
suitable for therapeutic evaluations (25).
Regarding the different methods of assessment used in
OA preclinical research, histological techniques continue to
be the “Gold Standards” in evaluating the disease progression
and the severity of the articular cartilage damage. However,
there is a great variety of microscopic scoring evaluations
which make the comparisons between studies challenging (26).
Additionally, these types of histologic evaluations may be
partially influenced by assessor’s subjectivity and they only
provide qualitative and partially quantitative information (32,
33). Technological advances related to two-dimensional (2D)
image analysis systems allow gaining significant objectivity,
precision and reproducibility in quantifying main histological
parameters reflecting the OA features at the synovial joint
tissues, including the subchondral bone component. As for
the latter, histomorphometry appears to remain the most
suitable technique for this purpose as it can be conducted
on undecalcified samples, which improves the knowledge on
the bone compartment (34–39). Regarding the non-invasive
three-dimensional (3D) imaging techniques, magnetic resonance
imaging (MRI) and micro-computed tomography (micro-CT)
have proven to be accurate and suitable quantitative tools in the
study of the histological OA features as cartilage damage and
calcified tissues change (33, 40–42).
Although BPs have been largely studied for the past two
decades, the evidence of their efficacy continues to be deficient
and important differences between preclinical and clinical
findings are still present. Additionally, there is a significant lack of
evidence on evaluating their effectiveness on the long term, and
only a few preclinical studies have investigated their effects after
6 months of treatment (20, 43). This manuscript focused on the
histological modifying-effects of risedronate on hyaline cartilage
and subchondral bone, after 24 weeks of treatment, considering
its possible positive impact by reducing the periarticular bone
turnover (11, 16, 17, 23, 44). In this line of research, the
long-term risedronate effect on the synovial structures has
recently been evaluated by macroscopically and decalcified
histology assessments as well as micro-CT general analysis
(45). However, on this occasion, a thorough 2D undecalcified
histomorphometric protocol was used for the study of the
quantitative cartilage and bone changes. Besides, we assessed the
3D site-specific microarchitecture fluctuations of the trabecular
bone, comparing them with the results observed in the 2D
histomorphometry. To the best of the authors’ knowledge, there
are no studies that focused on the stereological characterization
and quantitative evaluation of the risedronate use on cartilage,
subchondral bone plate and trabecular bone in the rabbit ACLT
model in an advanced stage of OA.
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The study is aimed at quantitatively determine whether
the antiresorptive therapies such as risedronate, may act as
osteoarthritic disease-modifying drugs in the long term. The goal
was to gain further insight into the microscopic degenerative
changes in the properties of the different cartilage layers
and subchondral bone, their precise anatomical location, as




Twenty-four healthy adult male New Zealand White rabbits
(Granja San Bernardo, Navarra, Spain) with a mean body weight
of 5 kg were used in this study upon approval of the protocol
by the Ethical Committee of the University of Santiago de
Compostela (Spain) (Reference number: 01/16/LU-002). The in
vivo procedures were conducted according to the Spanish and
European Union regulations about care and use of research
animals and this paper was written following the Animals in
Research Reporting In Vivo Experiments (ARRIVE) guidelines
(46). The animal housing and experimental procedures were
conducted in the Animal Experimentation Facility of the
University of Santiago de Compostela (Lugo, Spain) in ventilated
and enriched individual rabbit cages (R-suite, Tecniplast, Varese,
Italy) in a humidity- and temperature-controlled room kept
on a regular 12 h light/dark cycle. Food and tap water were
provided ad libitum. All efforts were made to minimize animals’
pain and distress as well as to reduce the number of animals
used. Environmental enrichment included supply of previously
autoclaved herb, fresh fruit, paper rolls and wood sticks. All
animals were monitored daily by accredited veterinarians trained
in laboratory animal science, who checked their health status,
body weight and signs of pain and discomfort. The rabbits were
acclimated for 3 weeks prior to being used in the study.
The anesthetic protocol and the postoperative treatment was
thoroughly described in a recent publication of our research
group (45). Osteoarthritis was surgically induced by ACLT and
partial medial meniscectomy achieving the instability of the knee
joint. Only one randomly selected knee per animal was operated,
using the contralateral as healthy control (HT). Eight out of the
24 included rabbits belonged to the sham operated control group.
For sham surgery, a similar joint exposure was made in one of the
knees but in this case the anterior cruciate ligament and medial
meniscus were left intact. Post-operatively, animals were allowed
to perform free activity without joint immobilization.
Treatments began 3 weeks after the OA induction and were
administered over a 24-week period by blinded personnel.
Rabbits were divided into three groups of eight animals each,
according to a computer-generated randomization list, as follows:
the treated group (RIS) received a 2.5mg once-weekly oral dose
of risedronate, whereas the untreated control group (CONT)
and the surgery control group (SHAM) received only saline as
vehicle (NaCl 0.9%). The animals were euthanised at 27 weeks
post-surgery by a sodium pentobarbital injection in the lateral
auricular vein (100 mg/kg IV, Dolethal, Vétoquinol, Madrid,
Spain), after sedation with ketamine (25 mg/kg IM, Imalgène
1000, Merial, Toulouse, France) and medetomidine (50 µg/kg
IM, Domtor, Esteve, Barcelona, Spain). As mentioned in a
previous publication (45), the risedronate dosage used in the
study corresponds to the human clinical doses recalculated
according to the mean weight of the animals.
Both knee joints were carefully dissected by sawing femora
and tibias to characterize the progression of the osteoarthritic
disease. The harvested knees were classified into the following six
groups: (1) surgery control group-operated knees with placebo
saline treatment (SHAM-OA, n = 8), (2) surgery control group-
non-operated knees with placebo saline treatment (SHAM-
HT, n = 8), (3) operated knees with placebo saline treatment
(CONT-OA, n = 8), (4) non-operated knees with placebo
saline treatment (CONT-HT, n = 8), (5) operated knees with
risedronate treatment (RIS-OA, n = 8), and (6) non-operated
knees with risedronate treatment (RIS-HT, n = 8) (Figure 1).
Harvested specimens were preserved in 10% neutral buffered
formalin and were destined for histomorphometry.
Histology
Histological Preparation
Stifle joints were carefully dissected and standardized sections
were obtained using a band saw from the middle region of each
medial and lateral femoral condyle (MFC, LFC) and tibia plateau
(MTP, LTP). Later, they were processed for undecalcified ground
sections according to the method described by Donath (47). In
summary, the fixed specimens were dehydrated in ascending
grades of ethanol, and then infiltrated and embedded with a
light curing methylmethacrylate resin (Technovit 7200-VLC,
Heraus Kulzer GmbH, Werheim, Germany). Sections were cut
and polished using a grinding machine (EXAKT Apparatebau,
Norderstedt, Germany) up to ∼40µm in thickness and stained
with Lévai-Laczkó.
Histomorphometric Analysis
Undecalcified histological samples were converted into digital
format using a motorized light microscope containing a
digital camera connected to a PC-based image capture system
(BX51, DP71, Olympus Corporation, Japan). All the sections
were observed and captured at magnifications up to x4.
The microscopic histomorphometric evaluation was performed
according to a previous publication of our research group
(16). For that purpose, we used the following PC-based image
analysis programs: Cell-sens 1.5 (Olympus Corporation, Japan)
and Image-Pro Premier 9.0.4 (Media Cybernetics, Bethesda,
MD, USA). All samples were presented in random order and
were processed and evaluated by two experienced observers,
blinded to the treatment received and the rabbit group. The
cartilage and subchondral bone thickness, the fibrillation index
and the trabecular subchondral bone area analysis were evaluated
as follows.
Firstly, a standardized region of interest (ROI) was defined
at the margins of cartilage, located superiorly and inferiorly
in the femur condyles, as well as laterally and medially in the
tibial plateaus. The established ROI was divided into four equal
distance zones (Z1 to Z4) with the purpose of reliably represent
the total extent of the lesions on these surfaces. At each area,
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FIGURE 1 | Diagram showing the schedule of the experimental design. SHAM group, surgery control group; CONT group, placebo treated group; RIS group,
risedronate treated group; OA knee, operated osteoarthritic knee; HT knee, healthy contralateral knee.
the cartilage surface and the junction between the uncalcified
cartilage and calcified cartilage, corresponding to the tidemark
line, were drawn. Furthermore, the junction points between the
calcified cartilage and the subchondral bone plate and between
the latter and the epiphyseal trabeculae bone initiation were
identified and traced (Figure 2).
The following measurements of cartilage and subchondral
bone thickness were calculated separately from the four
histological zones of the ROI from each lateral and
medial femorotibial joint compartments and expressed as
mean distances:
(A) Non-calcified cartilage thickness (nCg.Th, µm): as the
mean distance between the articular cartilage surface and
the tidemark.
(B) Calcified cartilage thickness (cCg.Th, µm): as the mean
distance from the tidemark to the subchondral bone plate.
(C) Total cartilage thickness (CgTh, µm): as the sum of the
thickness of uncalcified and calcified layer.
(D) Subchondral bone cortical thickness (SB.Th, µm): as the
mean distance between the subchondral bone plate and the
trabecular bone initiation.
Additionally, the degree of the superficial fissures and surface
undulations of the upper cartilage was quantified in all four zones
of the femur and tibial compartments. This fibrillation index (FI)
was assessed and calculated as the difference between the length
of the cartilage surface (L) and a straight parallel with the same
width line (W) (Figure 2).
Concerning the trabecular analysis, the ROIs were defined
on the central midpoint of the femur and tibia digital
images including the subchondral trabecular bone underlying
the articular cartilage with a size of 2.5 × 1.5mm for the
femur samples and 1.5 × 1.5mm for the tibias (Figure 3).
The trabecular subchondral bone parameters evaluated were:
Trabecular area (Tb.A, %), trabecular thickness (Tb.Th, mm),
trabecular separation (Tb.S, mm), and trabecular number
(Tb.N, 1/mm).
Micro-Computed Tomography Evaluation
In order to measure the 3D structural parameters of the
trabecular bone, the distal part of the femur and proximal
part of the tibia were scanned with a high-resolution micro-
CT (Skyscan 1172, Bruker microCT NV, Kontich, Belgium)
using parameters according to our previous study (45). In
order to evaluate the specific regional changes and based on
the method described by Batiste et al. (40), the knee was
examined at the lateral and medial sides of femoral condyles
and tibial plateaus and three cylindrical volumes of interest
(VOIs), of ×2.5mm of diameter and 2.5mm depth for femoral
compartments and 2.5 × 1.5mm for tibial compartments, were
placed in separate anatomical regions: anterior, central and
posterior (Figure 4). Additionally, the central VOIs of both
femoral and tibial samples were compared and correlated with
the previous 2D histologic findings of the trabecular bone. The
following indices of cancellous bone microarchitecture were
evaluated: bone volume fraction (BV/TV,%), trabecular thickness
(Tb.Th, mm), trabecular separation (Tb.S, mm), and trabecular
number (Tb.N, 1/mm).
Statistical Analysis
Data were expressed as means ± standard deviations (SDs).
All analyses were performed using SigmaPlot 12.5 software
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FIGURE 2 | Representative images of histomorphometric analysis. (A) Femoral condyle ROI; (B) Tibial plateau ROI; (C) Fibrillation index (FI) calculated as the
difference between the length of the cartilage surface (L) and a straight parallel with the same width line (W); (D) Cartilage and subchondral bone thickness: cCg.Th,
non-calcified cartilage thicknes; cCg.Th, calcified-cartilage thickness; Cg.Th, total cartilage thickness; SB.Th, subchondral bone cortical thickness.
(Systat Software inc., Chicago, IL, USA). The normality of the
data was assessed using the Shapiro-Wilk test and Levene’s
test was employed to assess the equality of variances of
normal variables. The differences between the two groups
were tested for significance by Student’s t-test or by two-tailed
Mann-Whitney U-test when data did not follow a normal
distribution. For statistical analysis among the three different
groups, means were compared using a one-way ANOVA and by
applying a post-hoc Holm-Sidak test. For non-normal variables,
the statistical comparison was performed using the Kruskal-
Wallis H-test and the post-hoc analysis using Dunn’s test.
Pearson’s correlation analyses were performed between the
undecalcified histology trabecular parameters and the micro-CT




During the experimental procedures no changes in weight
or general condition were observed. All surgeries were
performed without complications. The animals successfully
tolerated the treatments and no adverse reactions to
risedronate or vehicle were noted. Only one rabbit
belonging to the SHAM group died suddenly due to an
unknown reasons.
Histomorphometric Results
A total of 184 histological blocks were obtained. Out of these,
five were excluded from the histomorphometric analysis due to
excessive slicing artifact or incorrect anatomical section, whereas
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FIGURE 3 | Trabecular subchondral bone histology measurements. (A) Femoral ROI (1.5 × 2.5mm) (B) Tibial ROI (1.5 × 1.5mm). Tb.A: % of trabecular bone in the
ROI; Tb.Sp measured on the diagonal of the ROI [Tb.Sp = (L/Tb.N)-Tb.Th].
FIGURE 4 | Transverse micro-CT slices indicating the anatomical VOIs of cancellous bone evaluated. (A) Distal femur; (B) Proximal tibia. M, medial; L, lateral; a,
anterior; c, central; p, posterior.
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179 of them were finally included for assessment. Results can be
summarized in three points.
Cartilage and Subchondral Bone Cortical Thickness
Histomorphometric analysis data of the cartilage and
subchondral bone thickness for undecalcified femoral condyles
and tibial plateaus are shown in Tables 1, 2 respectively.
Regarding the cartilage parameters analyzed in the femoral
and tibial compartments, we observed a significant increase of the
Cg.Th in the injured knees corresponding to CONT-OA and RIS-
OA animals vs. their contralateral healthy joint. Furthermore, a
markedly increased Cg.Th was observed at the medial tibial sides
in both injured and not injured knees. Regarding the cartilage
areas, the highest values were shown in Z1 and Z2 in all the
examined tibias.
The separate analysis of the layers of cartilage of femoral
condyles and tibial plateaus, revealed that the uncalcified layer
showed significantly higher thickness values in the osteoarthritic
joints compared to the healthy ones, in agreement with what was
observed in the Cg.Th analysis. Once again, MTP samples and
tibial Z1 and Z2 revealed the higher thickness measurements.
With regard to the calcified level, small differences in the
statistical analysis were observed between groups. However,
RIS-OA and CONT-OA appeared to show a little tendency
toward thickening of the calcified cartilage, with the exception
of the observed in the CONT-OA group of the medial tibial
compartment, where a marked reduction in cCg.Th was outlined.
In summary, osteoarthritic joints showed the highest
thickness values, as well as MTP in all the evaluated knees.
Additionally, risedronate treatment did not have the capacity to
prevent the cartilage thickening and no significant differences
were found when comparing with the untreated-control group.
As for the SB.Th, in the analysis of the femoral condyles, no
significant differences were found between risedronate-treated
animals and untreated-control groups (SHAM and CONT) and
neither between the lateral and medial condyles. However,
we noticed that the osteoarthritic joints (CONT-OA and RIS-
OA) showed the lowest values of all the groups and these
differences were significant in some of the areas analyzed when
comparing with HT joints. With respect to tibial plateaus, the
main statistical difference was found between the lateral and
medial compartment, showing significant higher thickness values
at the MTP in both OA and HT joints. Regarding the separate
analysis of healthy groups, risedronate administration showed
a tendency to increase the SB.Th values compared to untreated
rabbits (CONT-HT and SHAM-HT). As observed in terms of
cartilage thickness, Z1 and Z2 generally revealed the highest
thickness measurements in all the tibial analyzed groups.
Fibrillation Index
The results of the FI evaluation are summarized in Table 3.
Regarding the degree of superficial fissures and surface
undulations of articular cartilage, CONT-OA and RIS-OA
animals showed the highest values in all the compartments
and all the evaluated zones. It is therefore important to
note that risedronate therapy did not seem to improve the
cartilage pathological changes and no significant differences
were found when comparing placebo control and risedronate-
treated OA groups. As far as the location is concerned, medial
compartments seemed to show more surface fibrillation than
lateral compartments. However, in relation to the results when
analyzing the four included successive zones, the values were
too variable to draw any conclusions. Regarding HT joints,
we noticed that the values were slightly higher in the medial
compartments compared to the lateral ones, especially in the
medial tibial side. Additionally, although we found no significant
differences between SHAM-HT and SHAM-OA groups, a slight
increase in the FI scores was observed in the osteoarthritic sham
animals in comparison to the healthy ones.
Trabecular Subchondral Bone Analysis
Regarding the trabecular parameters evaluated by 2D
histomorphometry (Table 4), there were no statistical significant
differences in any of the parameters measured in the femoral
compartments. Concerning tibial samples, the only significant
differences were found in the Tb.A when comparing CONT-OA
and CONT-HT as well as, CONT-OA and SHAM-OA, showing
lower values in the injured animals. Additionally, we noticed
that lateral tibial compartment exhibited the highest values in all
HT and OA joints. No significant differences were found in the
evaluation of the Tb.Th and Tb.Sp among groups. However, the
LTP showed less trabecular separation than that observed in the
other synovial compartments. Tb.N measurements were also not
statistically significant between treated and untreated-groups,
but significant decreased values were found when comparing the
medial side against the lateral side and also, when comparing
CONT-OA with CONT-HT groups at the MTP.
Micro-Computed Tomography Results
Micro-CT trabecular data of the structural parameters evaluated
in the three VOIs selected (central, anterior and posterior) are
available on Supplementary Tables 1–3, respectively.
The main statistical differences in the most of the analyzed
parameters were found in the OA joints (CONT-OA and
RIS-OA) compared to the HT contralateral limbs showing
decreased BV/TV, Tb.Th and Tb.N, as well as increased Tb.Sp.
Regarding the surgery control groups, although there were hardly
any statistical differences between SHAM-HT and SHAM-OA,
slightly higher osteoarthritic trabecular changes were identified
in the latter. Overall, no significant differences were found
between lateral and medial sides in almost any of the parameters
analyzed, nor between femoral and tibial compartments.
Additionally, in the risedronate-treated animals, altered
trabecular bone properties were identified in both HT and OA
joints. A significant increase Tb.Sp was observed when compared
to the SHAM groups in femoral and tibial compartments, and
occasionally, even to the CONT animals. Regarding the Tb.N,
the risedronate-treated groups (RIS-OA and RIS-HT) generally
showed the lowest values, with significant differences when
comparing them to the SHAM OA and HT groups, respectively
(Figure 5).
With regard to the relationship between the trabecular
parameters obtained by micro-CT and undecalcified histology
(Table 5), significant correlations were found for Tb.Sp (r =














































TABLE 1 | Stereologic histomorphometric analysis of femoral condyles.
nCg.Th (µm) cCg.Th (µm) Cg.Th (µm) SB.Th (µm)
Zones LFC MFC LFC MFC LFC MFC LFC MFC
Osteoarthritis joints (OA) SHAM 1 308.90 ± 94.56 330.86 ± 98.76 155.99 ± 64.04 165.52 ± 41.11 462.96 ± 116.13 495.34 ± 125.70 327.34 ± 117.29 257.53 ± 84.60
2 324.88 ± 74.29 365.82 ±80.27 153.15 ± 28.41 193.63 ± 47.70 474.91 ± 90.49 557.12 ± 91.03 400.54 ± 125.70 370.94 ± 86.77
3 329.37 ± 94.66 415.71 ± 99.98 120.18 ± 22.60 137.74 ± 28.03 446.10 ± 103.23 506.05 ± 132.71 464.52 ± 182.24 390.99 ± 124.91
4 318.09 ± 99.83 406.77 ± 103.82 105.39 ± 27.51 124.60 ± 33.33 423.14 ± 106.76 530.56 ± 105.02 254.97 ± 82.21 343.54 ± 84.17
CONT 1 519.96 ± 206.74a 481.48 ± 126.99 156.13 ± 57.80 178.30 ± 55.83 679.75 ± 240.83 658.65 ± 161.95 216.44 ± 92.95 247.97 ± 80.33
2 500.51 ± 221.56 453.46 ± 128.61 182.99 ± 69.47 172.87 ± 65.37 685.02 ± 278.19 620.49 ± 185.88 331.67 ± 167.10 269.48 ± 98.21
3 483.63 ± 119.97 421.07 ± 164.20 159.25 ± 73.16 114.58 ± 36.88 638.70 ± 179.83 530.08 ± 174.27 280.06 ± 154.66 317.07 ± 98.58
4 576.74 ± 147.42a 390.96 ± 176.58+ 139.42 ± 39.04 94.20 ± 24.14+ 714.92 ± 153.58a 480.58 ± 191.40+ 169.17 ± 99.66 262.29 ± 138.16
RIS 1 555.21 ± 87.53a 508.75 ± 203.74 150.57 ± 49.70 185.78 ± 60.75 695.67 ± 115.65 686.94 ± 250.60 267.65 ± 77.55 312.61 ± 125.55
2 477.58 ±155.29 501.66 ± 184.39 183.91 ± 58.57 223.89 ± 69.80 655.04 ± 206.34 722.64 ± 167.32 332.99 ± 104.37 256.35 ± 96.83
3 442.43 ±180.42 637.37 ± 189.86a,b 143.44 ± 81.24 169.28 ± 61.28 581.91 ± 253.02 801.84 ± 224.31a,b 320.39 ± 92.21 241.98 ± 79.14a
4 503.73 ± 81.70a 555.99 ± 104.28 151.74 ± 60.20 135.82 ± 46.21 647.00 ± 123.13a 684.50 ± 119.92a 223.49 ± 52.11 306. 57 ± 94.30
Healthy joints (HT) SHAM 1 187.96 ± 51.80* 345.11 ± 92.90+ 93.50 ± 33.56 157.47 ± 47.32+ 279.78 ± 81.84* 499.57 ± 107.12+ 357.18 ± 50.95 270.02 ± 120.21
2 298.93 ± 42.93 375.193 ± 101.50 139.71 ± 35.01 179.88 ± 38.21 436.22 ± 60.13 551.63 ± 132.76 412.94 ± 88.09 414.38 ± 182.44
3 275.33 ± 67.19 415.01 ±59.70+ 114.84 ± 20.94 136.18 ± 27.35 385.43 ± 77.95 547.17 ± 83.06+ 381.37 ± 131.04 398.48 ± 99.51
4 273.85 ± 104.86 395.309 ± 94.28+ 91.46 ± 13.61 110.76 ± 14.67+ 363.94 ± 107.23 502.66 ± 99.82+ 289.10 ± 130.79 410.66 ± 110.49
CONT 1 270.71 ± 112.06* 352.038 ± 142.82 127.27 ± 31.66 136.82 ± 44.53 392.74 ± 118.67* 486.68 ± 157.12* 293.45 ± 70.42 261.75 ± 121.34
2 337.71 ± 105.37 307.72 ±105.11* 154.01 ± 51.17 148.29 ± 33.92 488.72 ± 151.53 473.86 ± 101.51 315.12 ± 69.24 307.66 ± 114.08
3 311.21 ± 81.48* 389.43 ±71.77 119.68 ± 35.47 107.27 ± 18.16 427.00 ± 115.35* 491.58 ± 72.94 377.62 ± 118.35 353.68 ± 94.66
4 301.60 ± 119.09* 378.59 ± 76.42 103.76 ± 20.98 98.21 ± 21.52 383.28 ± 136.76* 474.60 ± 101.13 330.52 ± 124.97* 363.32 ± 124.07
RIS 1 267.70 ± 95.34* 365.59 ± 29.61+ 124.91 ± 34.24 144.53 ± 17.25 387.02 ± 118.90* 505.33 ± 24.50 346.58 ± 88.60 283.84 ± 92.94
2 326.144 ± 105.42* 373.23 ± 42.66 139.70 ± 37.32 167.99 ± 24.86 460.85 ± 137.65 536.94 ± 65.82* 329.63 ± 150.10 378.58 ± 99.57*
3 318.97 ± 125.91 369.63 ± 56.93* 117.78 ± 37.60 120.38 ±17.54 431.95 ± 160.30 483.11 ± 59.60* 367.75 ± 84.70 395.36 ± 80.62*
4 299.68 ± 119.45* 400.02 ± 89.15* 114.78 ± 25.32 85.28 ± 7.08a,+,* 411.29 ± 141.35* 478.52 ± 91.36* 291.06 ± 80.93 374.99 ± 145.58
Hismorphometric results: LFC, lateral femoral condyle; MFC, medial femoral condyle, nCg.Th, non-calcified cartilage thickness; cCg.Th, calcified cartilage thickness; Cg.Th, total cartilage thickness; SB.Th, subchondral bone thickness.
































































































TABLE 2 | Stereologic histomorphometric analysis of tibial plateaus.
nCg.Th (µm) cCg.Th (µm) Cg.Th (µm) SB.Th (µm)
Zones LTP MTP LTP MTP LTP MTP LTP MTP
Osteoarthritis joints (OA) SHAM 1 477.85 ± 87.59 651.52 ± 239.86 132.71 ± 27.66 91.97 ± 24.13+ 610.60 ± 82.71 739.17 ± 236.18 427.174 ± 88.81 450.75 ± 71.12
2 516.90 ± 88.22 816.82 ± 284.96 89.06 ± 20.43 71.08 ± 7.07+ 600.96 ± 75.35 878.18 ± 275.86 458.98 ± 54.92 529.07 ± 130.33
3 273.57 ± 42.13 658.05 ± 203.22+ 79.90 ± 10.86 72.52 ± 19.39 350.39 ± 43.55 731.08 ± 196.87 317.31 ± 107.64 438.12 ± 65.29+
4 154.02 ± 19.43 370.04 ± 129.92+ 80.32 ± 20.40 100.53 ± 27.12 232.41 ± 32.61 470.20 ± 139.73+ 173.11 ± 65.72 347.09 ± 74.64+
CONT 1 593.95 ± 310.96 782.83 ± 279.39 137.28 ± 60.04 82.45 ± 29.86+ 735.34 ± 329.55 866.93 ± 253.20 302.43 ± 104.14a 489.89 ± 109.80+
2 656.44 ± 186.21 974.09 ± 97.23+ 120.49 ± 49.42 57.11 ± 10.70+ 772.27 ± 173.82 1024.82 ± 97.94+ 289.07 ± 116.07a 368.61 ± 65.58
3 529.06 ± 152.64a 740.43 ± 188.85+ 133.90 ± 85.47 61.51 ± 21.26+ 668.31 ± 97.68a 796.80 ± 209.01 235.30 ± 62.88 321.82 ± 72.56a,+
4 362.98 ± 22.87a 553.92 ±125.38 90.03 ± 34.99 107.45 ± 35.75 450.37 ± 246.42 650.23 ± 131.00 166.96 ± 102.31 393.51 ± 93.84+
RIS 1 585.26 ± 268.53 680.26 ± 210.67 131.93 ± 29.77 125.34 ± 64.07b 710.52 ± 285.12 831.21 ± 202.79 384.59 ± 73.25 440.46 ± 167.95
2 567.66 ± 245.37 804.24 ± 284.64 101.72 ± 42.97 91.78 ± 33.42b 659.43 ± 244.29 888.42 ± 272.78 373.51 ± 84.08 413.30 ± 141.63
3 419.49 ± 142.92 653.24 ± 224.08+ 108.92 ± 40.63 95.67 ± 39.28b 522.68 ± 132.44a,b 742.22 ± 194.12 258.47 ± 84.88 354.66 ± 133.07
4 276.14 ± 146.47a 503.90 ± 178.04+ 80.51 ± 24.53 141.45 ± 65.23+ 349.39 ± 163.45 638.52 ± 160.86+ 220.39 ± 90.87 461.08 ± 257.66+
Healthy joints (HT) SHAM 1 421.83 ± 95.72 718.42 ± 165.38+ 133.76 ± 32.92 87.53 ± 14.26+ 553.27 ± 88.79 808.22 ± 166.26+ 491.91 ± 294.44 499.98 ± 54.85
2 436.50 ±128.13 1034.55 ± 113.86+ 93.74 ± 24.70 69.89 ± 13.39 525.42 ± 130.22 1104.39 ± 112.50+ 475.91 ± 186.53 494.55 ± 53.90
3 238.12 ± 76.55 682.82 ± 54.87+ 76.53 ± 23.41 63.23 ± 19.50 308.54 ± 89.78 737.32 ± 50.49 337.79 ± 118.75 409.40 ± 15.31+
4 145.04 ± 20.02 425.05 ± 67.06+ 67.49 ± 10.36 84.55 ± 16.23+ 208.44 ± 29.61 507.48 ± 59.71+ 192.37 ± 65.41 394.38 ± 81.84+
CONT 1 419.67 ± 151.53 767.16 ± 107.28+ 127.93 ± 31.99 71.07 ± 9.27+ 545.38 ± 136.55 840.47 ± 96.31+ 392.47 ± 63.95 421.64 ± 87.43
2 440.49 ± 182.26* 845.86 ± 108.91+,* 94.43 ± 19.75 66.39 ± 23.98+ 527.80 ± 167.95* 904.53 ± 103.87+,* 334.67 ± 65.4 395.35 ± 39.55
3 249.20 ± 138.75* 594.94 ± 107.93+ 79.75 ± 10.10 80.84 ± 31.63 322.68 ± 135.03* 672.21 ± 104.05 267.06 ± 27.61 360.44 ± 107.74
4 141.05 ± 44.82* 366.88 ± 84.21+,* 83.28 ±15.92 106.79 ± 39.36 223.34 ± 41.38* 472.43 ± 65.06+,* 180.04 ± 44.90 326.89 ± 80.28+
RIS 1 533.57 ± 242.19 688.92 ± 220.71 113.86 ± 31.79 95.24 ± 36.13* 649.99 ± 236.22 765.12 ± 199.43 496.55 ± 160.81 551.99 ± 180.55
2 456.03 ± 171.77 975.63 ± 220.71+ 89.28 ± 15.88 99.35 ± 48.59 537.55 ± 172.79 1075.03 ± 364.61+ 466.38 ± 120.40 545.6 ± 112.96b
3 263.61 ± 109.89* 700.06 ± 255.60+ 75.67 ± 11.57* 78.20 ± 37.76 334.56 ± 116.09* 773.25 ± 236.94 437.28 ± 112.07b,* 464.89 ± 69.86*
4 137.53 ± 44.01* 406.59 ± 150.94+ 81.32 ± 20.11 92.25 ± 46.79 216.84 ± 58.59* 501.60 ± 147.15+,* 259.82 ± 40.98a,b 362.35 ± 91.63+
Hismorphometric results: LTP, lateral tibial plateau; MTP, medial tibial plateau, nCg.Th, non-calcified cartilage thickness; cCg.Th, calcified cartilage thickness; Cg.Th, total cartilage thickness; SB.Th, subchondral bone thickness. Values
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TABLE 3 | Fibrillation index in the four evaluated zones (Z1 to Z4).
Osteoarthritis joints (OA) Healthy joints (HT)
Z1 Z2 Z3 Z4 Z1 Z2 Z3 Z4
SHAM LFC 1.040 ± 0.018 1.030 ± 0.024 1.047 ± 0.053 1.086 ± 0.055 1.020 ± 0.010* 1.010 ± 0.010 1.030 ± 0.010 1.051 ± 0.024
MFC 1.052 ± 0.028 1.024 ± 0.031 1.104 ± 0.102 1.110 ± 0.063 1.043 ± 0.031+ 1.034 ± 0.025+ 1.069 ± 0.037+ 1.081 ± 0.041
LTP 1.045 ± 0.093 1.011 ± 0.019 1.011 ± 0.007 1.021 ± 0.041 1.011 ± 0.015 1.010 ± 0.016 1.010 ± 0.009 1.040 ± 0.051
MTP 1.068 ± 0.064 1.194 ± 0.233+ 1.086 ± 0.112 1.066 ± 0.070 1.084 ± 0.054+ 1.100 ± 0.040+ 1.094 ± 0.045 1.090 ± 0.060
CONT LFC 1.040 ± 0.019 1.042 ± 0.054 1.059 ± 0.080 1.080 ± 0.033 1.032 ± 0.027 1.019 ± 0.012 1.031 ± 0.020 1.044 ± 0.024*
MFC 1.088 ± 0.050+ 1.153 ± 0.185a,+ 1.150 ± 0.170 1.141 ± 0.051+ 1.033 ± 0.025* 1.015 ± 0.011* 1.030 ± 0.015* 1.044 ± 0.008*
LTP 1.111 ± 0.095 1.152 ± 0.241 1.073 ± 0.095 1.092 ± 0.094 1.025 ± 0.039 1.020 ± 0.019 1.024 ± 0.021 1.006 ± 0.006*
MTP 1.179 ± 0.147 1.313 ± 0.251+ 1.234 ± 0.114 1.262 ± 0.146a 1.088 ± 0.050+ 1.105 ± 0.064+ 1.070 ± 0.074* 1.067 ±0.048*
RIS LFC 1.201 ± 0.170 1.133 ± 0.105 1.158 ± 0.120 1.126 ± 0.045 1.030 ± 0.022* 1.038 ± 0.036 1.025 ± 0.009* 1.058 ± 0.040*
MFC 1.170 ± 0.179 1.156 ± 0.077a 1.193 ± 0.176 1.195 ± 0.136 1.016 ± 0.012a,* 1.029 ± 0.031* 1.073 ± 0.062+ 1.075 ± 0.048*
LTP 1.147 ± 0.166 1.094 ± 0.149 1.083 ± 0.067 1.088 ± 0.141 1.023 ± 0.040* 1.013 ± 0.025* 1.026 ± 0.033* 1.010 ± 0.022*
MTP 1.136 ± 0.157 1.292 ± 0.252 1.241 ± 0.278 1.156 ± 0.099 1.066 ± 0.066 1.095 ± 0.074+ 1.085 ± 0.048 1.033 ± 0.043*
LFC, lateral femoral condyle; MFC, medial femoral condyle; LTP, lateral tibial plateau; MTP, medial tibial plateau. Values represent the mean and SD. Statistical sifnificant differences are
marked in “bold text.” p< 0.05: avs. SHAM, +vs. lateral compartment, *vs. OA joint.
TABLE 4 | Histomorphometrical trabecular analysis of healthy and OA joints.
Osteoarthritis joints (OA) Healthy joints (HT)
SHAM CONT RIS SHAM CONT RIS
Tb.A (%) Lateral femur 42.57 ± 5.15 49.57 ± 11.26 41.82 ± 8.46 46.76 ± 6.90 45.62 ± 5.77 47.54 ± 5.84
Medial femur 45.32 ± 3.77 44.58 ± 6.23 46.11 ± 11.04 50.95 ± 9.79 50.20 ± 9.18 50.74 ± 3.84
Lateral tibia 62.05 ± 3.70 48.99 ± 6.19a 54.74 ± 8.96 62.69 ± 5.36 61.62 ± 2.45* 58.24 ± 4.93
Medial tibial 49.44 ± 9.54+ 41.52 ± 8.56 45.70 ±11.85 51.40 ± 10.22+ 56.41 ± 7.63* 50.08 ± 9.47+
Tb.Th (mm) Lateral femur 0.429 ± 0.126 0.399 ± 0.177 0.447 ± 0.208 0.300 ± 0.121 0.340 ± 0.140 0.284 ± 0.071
Medial femur 0.431 ± 0.180 0.448 ± 0.208 0.304 ± 0.057 0.479 ± 0.263 0.470 ± 0.218 0.465 ± 0.196+
Lateral tibia 0.303 ± 0.075 0.260 ± 0.900 0.315 ± 0.111 0.371 ± 0.151 0.337 ± 0.063 0.331 ± 0.126
Medial tibial 0.354 ± 0.068 0.407 ± 0.170 0.277 ± 0.123 0.325 ± 0.069 0.336 ± 0.114 0.364 ± 0.099
Tb.Sp (mm) Lateral femur 0.425 ± 0.074 0.476 ± 0.192 0.420 ± 0.180 0.426 ± 0.202 0.360 ± 0.128 0.535 ± 0.109
Medial femur 0.423 ± 0.149 0.438 ± 0.199 0.344 ± 0.085 0.415 ± 0.141 0.439 ± 0.117 0.389 ± 0.155
Lateral tibia 0.222 ± 0.116 0.301 ± 0.093 0.242 ± 0.113 0.179 ± 0.077 0.223 ± 0.069 0.237 ± 0.073
Medial tibial 0.403 ± 0.245 0.404 ± 0.182 0.432 ± 0.244 0.441 ± 0.162+ 0.240 ± 0.083 0.352 ± 0.171
Tb.N (1/mm) Lateral femur 3.000 ± 0.632 3.125 ± 0.641 3.286 ± 0.756 3.429 ± 1.272 4.167 ± 0.983 3.625 ± 0.518
Medial femur 3.286 ± 0.951 3.750 ± 1.282 3.167 ± 1.329 3.286 ± 0.951 3.375 ± 0.744 3.250 ± 1.035
Lateral tibia 4.143 ± 0.690 3.875 ± 0.641 4.000 ± 0.926 3.833 ± 0.983 3.875 ± 0.641 3.571 ± 0.535
Medial tibial 3.000 ± 0.816+ 2.375 ± 0.518+ 2.750 ± 1.035+ 2.833 ± 0.408 3.857 ± 0.900* 3.250 ± 1.035
Histomorphometric scores of undecalcified samples: Tb.A, trabecular area; Tb.Th, trabecular thickness; Tb:Sp, trabecular separation; Tb:N, trabecular number; Values represent the
mean and SD. Statistical significant differences are marked in “bold text.” p< 0.05: avs. SHAM, +vs. lateral compartment, *vs. OA joints.
0.221, p < 0.001) and Tb.N (r = 0.210, p < 0.001). However,
these associations were not strongly correlated. Regarding the
BV/TV measurements from micro-CT, they were moderately
positive correlated with the histomorphometric Tb.A (r = 0.437,
p < 0.001). By contrast, there was no correlation for the Tb.Th
assessments (r = 0.026, p= 0.74).
DISCUSSION
The present study studied the histomorphometric quantitative
effects of risedronate on cartilage and subchondral bone in an
experimental rabbit model of OA after 6 months of treatment.
This stereologic analysis may contribute to a better evaluation
of the long-term therapeutic effect of bisphosphonates as
disease-modifying drugs for OA, also contributing to a better
understanding of the typical histological structural alterations in
rabbits as a preclinical OA model in an advanced stage.
Surgically induced models have some advantages, compared
to spontaneous models, such as a rapid onset and lower costs
(48). Nevertheless, the morphological changes are also usually
more severe and aminor therapeutic response could be observed,
which needs to be taken into account when the experiment
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FIGURE 5 | Micro-CT trabecular analysis on central VOI of osteoarthritic and healthy joints. (A) BV/TV, bone volumetric fraction; (B) Tb.Th, trabecular thickness; (C)
Tb:Sp, trabecular separation; (D) Tb:N, trabecular number. Values given as mean ± SD. Statistical significant differences p < 0.05: avs. SHAM, bvs. CONT, +vs. lateral
compartment, *vs. OA joints.
is designed (25). Concerning the rabbit as an experimental
animal model, although their histological osteoarthritic lesions
have been extensively studied by the scientific community
for numerous years (29, 33, 42), at present, there are still
some differences in the parameters analyzed between preclinical
studies. With reference to the anatomical location of the
pathological changes, Huang et al. (49) pointed out that at 16
weeks after surgery, rabbits showed partial or full thickness
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TABLE 5 | Mean values and correlation of Pearson coefficients between 2D histology and 3D micro-CT trabecular parameters.
Correlation between: 2D values (mean ± SD) 3D values (mean ± SD) r P-value
Tb.A and BV/TV (%) 50.07 ± 9.33 60.09 ± 11.46 0.437 <0.001
Tb.Th (mm) 0.373 ± 0.154 0.156 ± 0.026 0.026 0.74
Tb.Sp (mm) 0.362 ± 0.169 0.109 ± 0.042 0.221 <0.001
Tb.N (1/mm) 3.417 ± 0.938 3.905 ± 0.634 0.210 <0.001
Tb.A, trabecular area; BV/TV, bone volume fraction; Tb.Th, trabecular thickness; Tb.Sp, trabecular separation; Tb.N, trabecular number.
cartilage erosion, more marked in the MFC. These results were
consistent with the results of other researches, which reported
more pronounced degenerative bone changes in the femur and
in the medial compartment (33, 42). They were similar to
those observed in advanced human OA where the disease was
described as more severe in the medial compartment than in the
lateral one (50). In accordance with these findings, a recently
published study (45) observed that the medial femoral condyles
exhibited slightly greater macroscopic osteoarthritic changes. By
contrast, in this study, more structural changes were observed
in the cartilage and subchondral bone in terms of thickness
values of the MTP. However, one should take into account
that significantly higher thickness values were also observed in
HT joints, thus an increased thickness at that level could be
physiologically present in the ACLT rabbit model.
Regarding other preclinical models such as spontaneous OA
in guinea pig, authors also noticed more severe cartilage OA
changes on medial sides, as well as on the anterior region
(2). Moreover, Bagi et al. (51) observed that in contrast to
biped animals, rat models of OA tend to shift part of the
weight onto their front legs and not only onto the contralateral
limb as humans do. This observation was in agreement
with a previous publication, where no restabilization of the
damaged limb to the healthy was observed in rodents (25).
Nevertheless, in the experimental design it was important to
include non-surgically induced control animals (SHAM group),
in order to allow the identification of possible load-bearing
alterations toward the healthy limb (42). In our study, the
histomorphometric assessments showed that the experimental
surgical model induced degenerative changes on the articular
cartilage and the periarticular subchondral bone and additionally,
significant differences were found between the OA joints and the
contralateral HT joints in most of the analyzed parameters.
As previously discussed, one of the objectives of this
study was to elucidate whether these antiresorptive therapies
could somehow influence the OA progression, with special
interest in the subchondral bone response. Despite the fact
that osteoarthritis investigations should include all tissues that
make up the joint, articular cartilage generally continues to
be the primary focus of OA (34, 52, 53). To provide a wide
understanding of the osteoarthritic disease, various diagnostic
techniques may be necessary in preclinical research to properly
analyse all the synovial joint elements. Regarding, the new
proteomic studies are proving to be an interesting and powerful
tool for OA pathophysiology research (54). For the present
study, we used quantitative 2D histological histomorphometry
to assess the structural changes in cartilage and the subchondral
bone properties as well as 3D micro-CT scanning in order
to complete the trabecular bone characterization at different
anatomical locations.
Within the possible assessable histomorphometric
parameters, the cartilage thickness is the most widely evaluated
parameter in OA animal models and probably, one of the
easiest to quantify (32). Nevertheless, scientific publications
showed a great heterogeneity in their outcomes. On the one
hand, a cartilage surface degradation during OA progression
was described (36, 53, 55), but other studies was observed the
increase and the hypertrophy of the cartilage layers (2, 38, 39). In
accordance with the latter, we noticed a marked tendency toward
cartilage thickening in OA joints in all the anatomical sections
examined and these outcomes were especially pronounced in
the MTP. By contrast, Pinamont et al. (36) observed a decrease
in total cartilage and uncalcified cartilage areas in a surgical
mouse model 12 weeks after the OA induction, probably related
to cartilage fibrillation and even the complete degeneration of
the cartilage layer, during severe OA. In the same way, Hayami
et al. (53) found a significant uncalcified cartilage thinning in the
MTP in two surgically induced rat models, within 4–10 weeks
after surgery. Additionally, Hagiwara et al. (56) did not noticed
any significant differences in articular cartilage thickness using
an immobilization rat model. This lack of consistent results
regarding the cartilage thickness was related to the absence
of measurement protocols, the animal model and the use of
contralateral knees as controls (56). Concerning the latter, in our
study no statistical differences were identified between healthy
joints in any of the studied groups (including de SHAM-HT
group) suggesting the validity of the contralateral limb used as
HT control. As far as the BP response is concerned, in a previous
study of our research group (16) it was observed that short-term
risedronate therapy seemed to prevent the cartilage thickening,
showing similar values to those observed in the healthy control
animals. However, in this instance, we did not observe this
capacity in the long term and no statistical differences were
found compared to the placebo group.
Regarding the pathological changes in bone tissues, a
noticeable relationship between damaged cartilage and
underlying subchondral bone alteration was observed according
to several publications (2, 39, 51, 57). In concordance with
this, our analysis showed a trend toward subchondral bone
thinning beneath the cartilage alteration. By contrast, other
publications noticed a thicker subchondral bone layer in the
osteoarthritic joints (38, 57). In early or less severe stages
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of OA, Wang et al. (2) suggested that both cartilage and
subchondral bone tissue may initially respond by an increasing
remodeling activity which would be manifested as an uncalcified
cartilage layer increase. Conversely, the initial response of
the subchondral bone to mechanical stress could increase the
osteoclasts activity resulting in a thinner subchondral bone
plate. Although we did not find any significant differences in
the SB.Th of femoral condyles between the risedronate- and
placebo-treated groups, we observed that tibial plateaus with
a long-term risedronate administration showed slightly higher
thickness values, in both OA and HT joints, compared to
untreated animals. This occurrence could be associated to an
inhibition of bone-resorption activity at this level, related to the
BP administration.
The present study also evaluated the FI, which is considered
a histopathological indicator of collagen breakdown in OA
(55). Additionally, Hayami et al. described that focal fibrillation
was one of the first degenerative changes observed in the rat
surgical model (53). BP therapies demonstrated significant
chondroprotective effects in preclinical studies, showing
significantly milder ulcerations and less superficial cartilage
fibrillation (16, 58). By contrast, in our assessments after 6
months of treatment, risedronate did not seem to improve
the cartilage pathological changes, showing similar values
to those observed in untreated animals. In accordance with
other publications (35), the OA joints showed significant more
surface fibrillation than HT joints, especially in the medial
compartments. However, a recent research study has highlighted
that although this parameter may be indicative of the severity of
the cartilage, it may also decrease due to a complete erosion of
the cartilage surface in advanced stages of OA (36).
Regarding the results obtained in the trabecular micro-CT
analysis, the main changes were detected in the osteoarthritic
joints compared to the healthy ones, and were as follows:
reduced BV/TV, smaller Tb.Th and Tb.N, as well as increased
Tb.Sp. Our findings were consistent with other post-traumatic
studies using the ACLT rabbit model (33, 42) and canine model
(41), where it was observed an increased deterioration in the
quality of the trabecular bone with activated bone resorption
and consequently, decreased Tb.Th and bone volume. In contrast
to other publications, where increased trabecular bone loss was
observed on femoral condyles against tibial plateaus (33), overall
in our study, no significant differences between femoral and
tibial compartments were found in any of the VOIs analyzed. In
that regard, contradictory results were found between scientific
studies based on animal models and the experimental protocol.
Interestingly, and contrary to what it has been published in
some preclinical models, Bobinac et al. (50) observed in human
knee joints with osteoarthritis, a significant histomorphometry
increase in BV/TV and Tb.Th parameters, as well as decreased
values of Tb.N and Tb.S. As proposed by Chappard et al.
(59) the differences between human OA studies and those
observed in animal models, may be related to variations between
spontaneous and post-traumatic OA. Additionally, other factors
such as the presence of comorbid diseases should be take into
account and have been related with significant bone loss at
the subchondral plate. Specifically, it has been observed in
human knee OA patients with type 2 diabetes mellitus and
hypertension (60). With respect to the risedronate therapy
effectiveness, although several preclinical publications seemed
to show a positive subchondral bone preservation (16, 17, 23),
in our case, the long-term BP administration did not show
any beneficial effect on the osteoarthritic joints, showing lower
Tb.N and higher Tb.Sp values, similar to those observed in the
CONT-OA group. Interestingly, similar altered trabecular bone
properties were noticed in RIS-HT joints, and more specifically
it was observed in the central VOI. This could be explained
due to the inherent antiresorptive properties of these therapies,
but it could also be related to an altered load-bearing on the
contralateral healthy limb, showing statistical differences when
compared to the SHAM-HT group.
As other authors noticed (61), bone histomorphometry
presented some limitations associated with its 2D condition
and the slice selection and size, representing only a very
small fraction of the synovial tissue. The correlations observed
between 2D histomorphometry and micro-CT measurements
were weak, and there were hardly any significant differences in
the histological trabecular analysis among groups. By contrast,
micro-CT evaluation identified more accurate changes in the
cancellous bone microarchitecture.
The alterations observed in both cartilage and subchondral
bone reflected the concomitant response of those articular
tissues to the surgical instability and consequently, to the altered
biomechanical loads. As expected from increased focal load-
bearing associated with surgical location (medial meniscectomy),
cartilage tissues in medial compartments showed an increased
response to overloading, especially on the tibial compartment.
This is consistent with previous publications, where a faster
progression of OAwas observed in the tibial plateau compared to
femoral condyles (39). Nevertheless, in that sense we could expect
a more increased pathology in the middle zones (Z2 and Z3) of
femorotibial joints, but the measurements in femoral condyles
were too variable to establish the hypothesis. With respect to
tibial plateaus, the highest values were identified in Z1 and Z2,
corresponding to the inner zones.
Concerning the general BP effectiveness, in our study the
long-term risedronate administration did not seem to reduce the
osteoarthritic changes and failed to diminish the hypertrophic
response of cartilage, the surface fibrillation or prevent the
subchondral trabecular bone loss. Previous publications noted
that pre-emptive and early antiresorptive therapy initiations
showed better chondroprotective efficacy and subchondral bone
quality than delayed administrations (14, 62, 63). It is therefore
possible that our rabbit ACLT and partial medial meniscectomy
model developed the cartilage damage too fast and when we
started the risedronate administration, the observed changes
were already too severe. However, the real situation in affected
patients, in both human and veterinarymedicine, is that therapies
are usually initiated when the OA disease is advanced (14). For
this reason, early diagnostic techniques, such as new imaging
modalities and biochemical markers should provide a new
opportunity for the future management of the disease.
Our study is subject to several limitations. First, our analysis
included only 24 animals and there may be variability differences
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of some of the parameter measures. Additionally, some technical
challenges should be kept in mind, such as the high cost, the
highly trained personnel required and the slide selection, which
may not occur consistently. Lastly, another potential limitation
of the current study is that the histological techniques may not be
completely applicable in clinical situations.
In conclusion, it is important to note that the scientist
community is currently involved in carrying out the 3R principles
of replacement, reduction and refinement. Given that we adhered
to a policy of reducing animal numbers, we considered to be
appropriate to continue the research with the same experimental
animals (45) and consequently, complete the characterization of
the risedronate effect at all levels. The results of this study may
improve our knowledge about osteoarthritis anatomic location
and disease evolution, more specifically allowing an appropriate
tissue selection in the OA preclinical studies. Additionally, this
study provides novel information about the histomorphometry
quantitative effect of long-term bisphosphonate use as possible
disease-modifying drug in osteoarthritis.
CONCLUSIONS
In this study, the histomorphometric evaluations in the
rabbit surgical model were appropriate for the study of the
quantitative structural osteoarthritic changes, contributing to
a better evaluation of the long-term therapeutic efficacy of
bisphosphonates and also, to a better anatomical knowledge
of the animal model. Sample analysis demonstrated that
the experimental model induced osteoarthritic changes in
the operated joints. The histomorphometric analysis of the
undecalcified histology samples showed a marked tendency
toward cartilage thickening and cartilage fibrillation in the OA
joints in all the examined anatomical sections, as well as a
trend toward subchondral bone thinning beneath the cartilage
alteration. These outcomes were especially pronounced in the
medial tibial plateau and in the inner tibial zones. Additionally,
the trabecular evaluation showed a significant bone quality
loss in the operated limbs with decreased trabecular thickness,
trabecular number and bone volume, as well as increased
trabecular separation. The micro-CT analysis identified more
accurately the trabecular bone changes than the undecalcified
histology. Lastly, the long-term risedronate treatment did
not seem to have the capacity to reduce the osteoarthritic
hypertrophic cartilage response and failed to diminish the surface
fibrillation or prevent the trabecular bone loss.
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